Market Context — Why This Technology, Why Now

The global rise of antimicrobial resistance (AMR) and the push for personalized medicine are driving urgent demand for advanced diagnostic tools. Current methods often delay treatment, exacerbating AMR. This technology's ability to provide early, precise bacterial activity visualization aligns perfectly with these trends, offering a critical solution to improve patient outcomes and reduce healthcare burdens, estimated to save hundreds of millions of dollars annually in healthcare costs.

Key Competitive Advantages
01

Detects pre-symptomatic lesions earlier and more accurately than conventional methods.

02

Optimizes treatment strategies by visualizing bacterial activity in real-time, reducing antibiotic resistance risk.

03

Secures strong market uniqueness with minimal prior art, enabling early market share in a less competitive segment.

Market Opportunity
Healthcare Institutions (Hospitals & Clinics)
$1B globally (AI est.)
High demand for optimized treatment and improved patient outcomes through early diagnosis.
Large hospital networks Specialized infectious disease clinics Diagnostic imaging centers
Pharmaceutical & Biotech Companies
$20B globally (AI est.)
Expected application as a treatment efficacy evaluation tool in novel antibiotic development.
Major pharmaceutical R&D divisions Biotech firms developing anti-infectives Contract Research Organizations (CROs)
Research Institutions & Universities
$350M globally (AI est.)
Potential contribution as a fundamental and applied research tool in bacteriology and infectious disease studies.
Academic medical centers Government-funded research labs University infectious disease departments
IP Defensibility — Why Competitors Can't Replicate This
What This Patent Covers

This patent protects a bacterial infection diagnostic agent comprising specific radiolabeled compounds and amino acids, with claims clearly defining the scope of infringement. It demonstrates high originality with only two prior art documents cited by the examiner and was granted after successfully addressing examiner objections, indicating a robust and stable right.

Competitive White Space

White space exists in developing advanced AI-driven image analysis software for enhanced diagnostic precision, or integrating this agent with novel imaging modalities. Further IP could also be built around therapeutic applications that combine this diagnostic capability with targeted drug delivery systems.

Economic Impact
~$1.5M/year estimated healthcare cost and treatment duration reduction per facility (est.)
estimated ROI · USD · AI analysis
ROI Calculation Logic

If a licensee provides this technology to hospitals, early diagnosis could shorten hospital stays and reduce inappropriate antibiotic use. For example, for 1,000 bacterial infection patients annually, shortening average hospital stays by 5 days (at ~$650/day medical cost, AI est.) and reducing inappropriate antibiotic use by 20% (assuming ~$350/case drug cost, AI est.) could yield a total annual healthcare cost reduction potential of ~$3.5M (AI est.). Even accounting for diagnostic agent introduction costs, an annual economic impact of ~$1.5M is estimated (AI est.).

Speed to Market
5× faster than in-house development
This technology, developed as a research outcome by Kanazawa University, has established fundamental data on the uptake of specific radiolabeled compounds by bacteria. The accumulation trends across various bacterial species and growth phases have been thoroughly investigated, and the principle for a diagnostic agent is already proven. This allows licensees to bypass initial R&D, leveraging existing knowledge and data to rapidly advance to preclinical and clinical trials, significantly shortening time to market compared to in-house development.
Competitive Positioning

X: Diagnostic Accuracy & Early Detection
Y: Contribution to Treatment

Business Models & Applications
💊 Diagnostic Agent Licensing
A model for licensing the manufacturing and sales of diagnostic agents utilizing this technology to existing diagnostic drug manufacturers and medical device companies.
🤝 Joint Development & Commercialization
A model to collaboratively advance clinical development, regulatory approval, and commercialization of diagnostic agents based on this technology with a licensee.
🔬 Diagnostic Service Provision
A model to establish a testing center using this technology, offering precise diagnostic services for bacterial infections to healthcare institutions and pharmaceutical companies.
Adjacent Application Opportunities
🥩 Food Safety & Quality Control
Ultra-Early Detection of Food Contaminants
Applying this radiodiagnostic technology to food processing lines, such as for meat products or dairy, could enable earlier detection of bacterial contaminants than conventional culture methods, preventing foodborne illness risks. This could reduce product recalls by up to 30%.
💧 Environmental Monitoring
Visualize Water & Soil Bacterial Contamination
In environmental surveys of rivers and soil, this technology could non-invasively image the proliferation activity of specific pathogenic bacteria. This application could rapidly and accurately identify pollution sources and assess environmental risks, potentially cutting assessment times by 40%.
🐕 Veterinary Medicine
Early Diagnosis for Animal Bacterial Infections
Providing early and highly accurate diagnosis for bacterial infections in livestock and pets could optimize treatment and prevent infection spread. This contributes to animal health maintenance and could reduce economic losses in the livestock sector by millions of dollars annually.
Integration Roadmap — Estimated 42-Month Deployment
Foundational Data Validation & Regulatory Strategy
Duration: 6 months
Thoroughly evaluate foundational data accumulated by Kanazawa University and formulate a roadmap and regulatory requirements for obtaining diagnostic agent approval.
Preclinical & Clinical Trial Preparation
Duration: 12 months
Conduct preclinical safety (toxicity, pharmacokinetics) evaluations for the radiodiagnostic agent and develop clinical trial protocols to confirm human efficacy and safety.
Clinical Trials & Marketing Authorization
Duration: 24 months
Execute clinical trials based on the established protocols, then submit marketing authorization applications to domestic and international regulatory authorities for product commercialization.
Technical Feasibility
This technology images bacterial proliferation activity using a combination of radiolabeled compounds and amino acids, demonstrating high compatibility with existing nuclear medicine imaging equipment (PET/SPECT). Special new equipment investment is limited, allowing licensees to leverage existing infrastructure to establish diagnostic agent manufacturing and supply systems. With established foundational data, the technical implementation hurdle is considered relatively low.
Success Scenario
Implementing this technology could enable early detection of bacterial infections previously difficult to diagnose, potentially shortening the time to treatment by an average of 50%. This could reduce patient severity risk, cut hospital stays by 20%, and lead to annual healthcare cost savings in the hundreds of millions of dollars (AI est.). Furthermore, it could promote appropriate antibiotic use, contributing to the suppression of drug-resistant bacteria.
Patent Record
APPLICATION NO.
特願2020-207990
REGISTRATION NO.
7699792
FILING DATE
2020/12/15
GRANT DATE
2025/06/20
EXPIRATION DATE
2040/12/15
PATENT HOLDER
国立大学法人金沢大学
Examination History
2021年01月29日
手続補正書（自発・内容）
2023年12月07日
出願審査請求書
2024年12月19日
拒絶理由通知書
2025年02月11日
意見書
2025年02月11日
手続補正書（自発・内容）
2025年05月19日
特許査定